請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34055
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 胡芳蓉(Fung-Rong Hu) | |
dc.contributor.author | Yi-Chen Sun | en |
dc.contributor.author | 孫逸珍 | zh_TW |
dc.date.accessioned | 2021-06-13T05:52:52Z | - |
dc.date.available | 2006-08-02 | |
dc.date.copyright | 2006-08-02 | |
dc.date.issued | 2006 | |
dc.date.submitted | 2006-07-03 | |
dc.identifier.citation | Bainbridge JW, Mackie IA, Mackie I. Diagnosis of Theodore's superior limbic keratoconjunctivitis. Eye 1998;12 ( Pt 4):748-9.
Barr JT, Dugan PR, Reindel WR, Tuovinen OH. Protein and elemental analysis of contact lenses of patients with superior limbic keratoconjunctivitis or giant papillary conjunctivitis. Optom Vis Sci 1989;66:133-40. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477-588. Baum JL. The Castroviejo Lecture. Prolonged eyelid closure is a risk to the cornea. Cornea 1997;16:602-11. Bloomfield SE, Jakobiec FA, Theodore FH. Contact lens induced keratopathy: a severe complication extending the spectrum of keratoconjunctivitis in contact lens wearers. Ophthalmology 1984;91:290-4. Carpel EF. Superior limbic keratoconjunctivitis. Arch Ophthalmol 1984;102:662, 664. Chavis PS. Thyroid and the eye. Curr Opin Ophthalmol 2002;13:352-6. Cher I. Clinical features of superior limbic keroconjunctivitis in Australia. A probable association withhyrotoxicosis. Arch Ophthalmol 1969;82:580-6. Cher I. Superior limbic keratoconjunctivitis: multifactorial mechanical pathogenesis. Clin Experiment Ophthalmol 2000;28:181-4. Cher I. Blink-related microtrauma: when the ocular surface harms itself. Clin Experiment Ophthalmol 2003;31:183-90. Collin HB, Donshik PC, Boruchoff SA, Foster CS, Cavanagh HD. The fine structure of nuclear changes in superior limbic keratoconjunctivitis. Invest Ophthalmol Vis Sci 1978;17:79-84. Collin HB, Donshik PC, Foster CS, Boruchoff SA, Cavanagh HD. Keratinization of the bulbar conjunctival epithelium in superior limbic keratoconjunctivitis in humans. An electron microscopic study. Acta Ophthalmol (Copenh) 1978;56:531-43. Condon GP, Brownstein S, Codere F. Sebaceous carcinoma of the eyelid masquerading as superior limbic keratoconjunctivitis. Arch Ophthalmol 1985;103:1525-9. Confino J, Brown SI. Treatment of superior limbic keratoconjunctivitis with topical cromolyn sodium. Ann Ophthalmol 1987;19:129-31. Corona R, Abraham JL. Superior limbic keratoconjunctivitis apparently related to particulate material from a ventilation system. N Engl J Med 1989;320:1354. Corwin ME. Superior limbic keratoconjunctivitis. Am J Ophthalmol 1968;66:338-40. Darrell RW. Superior limbic keratoconjunctivitis in identical twins. Cornea 1992;11:262-3. D L. Conjunctivochalasis: a cause of tearing and its management. Ophthal Plast Reconstr Surg 1986;2:25-28. Donshik PC, Collin HB, Foster CS, Cavanagh HD, Boruchoff SA. Conjunctival resection treatment and ultrastructural histopathology of superior limbic keratoconjunctivitis. Am J Ophthalmol 1978;85:101-10. Eiferman RA, Wilkins EL. Immunological aspects of superior limbic keratoconjunctivitis. Can J Ophthalmol 1979;14:85-7. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea 2001;20:807-10. Grutzmacher RD, Foster RS, Feiler LS. Lodoxamide tromethamine treatment for superior limbic keratoconjunctivitis. Am J Ophthalmol 1995;120:400-2. Hatamochi A, Kuroda K, Shinkai H, Kohma H, Oishi Y, Inoue S. Regulation of matrix metalloproteinase (MMP) expression in cutis laxa fibroblasts: upregulation of MMP-1, MMP-3 and MMP-9 genes but not of the MMP-2 gene. Br J Dermatol 1998;138:757-62. Johnson LL DR, Hupe DJ. Matrix metalloproteinase. Curr Opin Chem Biol 1998;2:466-471. Kabat AG. Lacrimal occlusion therapy for the treatment of superior limbic keratoconjunctivitis. Optom Vis Sci 1998;75:714-8. Kadrmas EF, Bartley GB. Superior limbic keratoconjunctivitis. A prognostic sign for severe Graves ophthalmopathy. Ophthalmology 1995;102:1472-5. Kass LG, Hornblass A. Sebaceous carcinoma of the ocular adnexa. Surv Ophthalmol 1989;33:477-90. Kahari VM, Saarialho-Kere U. Matrix metalloptoteinases in skin. Exp Dermatol 1997;6:199-213 Kleiner DE Jr SSW. Structural biochemistry and activation of matrix metalloproteinases. Curr Opin Cell Biol 1993;5:891-897. Klein-Nulend J, Roelofsen J, Sterck JG, Semeins CM, Burger EH. Mechanical loading stimulates the release of transforming growth factor-beta activity by cultured mouse calvariae and periosteal cells. J Cell Physiol. 1995;163:115-9. Kobayashi TK, Tsubota K, Takamura E, Sawa M, Ohashi Y, Usui M. Effect of retinol palmitate as a treatment for dry eye: a cytological evaluation. Ophthalmologica 1997;211:358-61. Laughrea PA, Arentsen JJ, Laibson PR. Iatrogenic ocular silver nitrate burn. Cornea 1985;4:47-50. Li DQ, Meller D, Liu Y, Tseng SC. Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts. Invest Ophthalmol Vis Sci 2000;41:404-10. Mackie IA. Management of superior limbic keratoconjunctivitis with botulinum toxin. Eye 1995;9 ( Pt 1):143-4. Matsuda A, Tagawa Y, Matsuda H. Cytokeratin and proliferative cell nuclear antigen expression in superior limbic keratoconjunctivitis. Curr Eye Res 1996;15:1033-8. Matsuda A, Tagawa Y, Matsuda H. TGF-beta2, tenascin, and integrin beta1 expression in superior limbic keratoconjunctivitis. Jpn J Ophthalmol 1999;43:251-6. Meller D TS. Conjunctivochalasis: literature review and possible pathophysiology. Surv Ophthalmol 1998;43:225-232. Meller D, Li DQ, Tseng SC. Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha. Invest Ophthalmol Vis Sci 2000;41:2922-9. Mondino BJ, Brawman-Mintzer O, Boothe WA. Immunological complications of soft contact lenses. J Am Optom Assoc 1987;58:832-5. Mondino BJ, Zaidman GW, Salamon SW. Use of pressure patching and soft contact lenses in superior limbic keratoconjunctivitis. Arch Ophthalmol 1982;100:1932-4. Murakami Y, Kanamoto T, Tuboi T, Maeda T, Inoue Y. Evaluation of extraocular muscle enlargement in dysthyroid ophthalmopathy. Jpn J Ophthalmol 2001;45:622-7. Nelson JD. Superior limbic keratoconjunctivitis (SLK). Eye 1989;3 ( Pt 2):180-9. Ohashi Y, Watanabe H, Kinoshita S, Hosotani H, Umemoto M, Manabe R. Vitamin A eyedrops for superior limbic keratoconjunctivitis. Am J Ophthalmol 1988;105:523-7. Ostler HB. Superior limbic keratoconjunctivitis. In Smolin G, Thoft RA, eds. The Cornea, Boston/Toronto: Little Brown 1987:296-298. Passons GA, Wood TO. Conjunctival resection for superior limbic keratoconjunctivitis. Ophthalmology 1984;91:966-8. Perry HD, Doshi-Carnevale S, Donnenfeld ED, Kornstein HS. Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology 2003;110:1578-81. Raber IM. Superior limbic keratoconjunctivitis in association with scarring of the superior tarsal conjunctiva. Cornea 1996;15:312-6. Rodewald HR DM, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. Science 1996;271:818-822. Saika S, Minamide A, Tanaka T, et al. Expression of involucrin by ocular surface epithelia of patients with benign and malignant disorders. Curr Eye Res 2000;21:877-85. Schlotzer-Schrehardt U, Stojkovic M, Hofmann-Rummelt C, Cursiefen C, Kruse FE, Holbach LM. The Pathogenesis of floppy eyelid syndrome: involvement of matrix metalloproteinases in elastic fiber degradation. Ophthalmology 2005;112:694-704. Sendele DD, Kenyon KR, Mobilia EF, Rosenthal P, Steinert R, Hanninen LA. Superior limbic keratoconjunctivitis in contact lens wearers. Ophthalmology 1983;90:616-22. Stenson S. Superior limbic keratoconjunctivitis associated with soft contact lens wear. Arch Ophthalmol 1983;101:402-4. Sutherland AL. Superior limbic keratoconjunctivitis. Report of a case. Trans Ophthalmol Soc N Z 1969;21:89-95. Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR. The clinical efficacy of silicone punctal plug therapy. Cornea 2002;21:135-9. Tan DT, Ang LP, Beuerman RW. Reconstruction of the ocular surface by transplantation of a serum-free derived cultivated conjunctival epithelial equivalent. Transplantation 2004;77:1729-34. Theodore FH. Superior limbic keratoconjunctivitis. Eye Ear Nose Throat Mon 1963;42:25-8. Theodore FH. Further observations on superior limbic keratoconjunctivitis. Trans Am Acad Ophthalmol Otolaryngol 1967;71:341-51. Theodore FH. Comments on findings of elevated protein-bound iodine in superior limbic keratoconjunctivitis: I. Arch Ophthalmol 1968;79:508. Theodore FH. Superior limbic keratoconjunctivitis. Arch Ophthalmol 1983;101:1627-9. Theodore FH, Ferry AP. Superior limbic keratoconjunctivitis. Clinical and pathological correlations. Arch Ophthalmol 1970;84:481-4. Tseng SC. Staging of conjunctival squamous metaplasia by impression cytology. Ophthalmology 1985;92:728-33. Tsuzaki M, Bynum D, Almekinders L, Faber J, Banes AJ. Mechanical loading stimulates ecto-ATPase activity in human tendon cells. J Cell Biochem. 2005 96:117-25. Udell IJ, Guidera AC, Madani-Becker J. Ketotifen fumarate treatment of superior limbic keratoconjunctivitis. Cornea 2002;21:778-80. Udell IJ, Kenyon KR, Sawa M, Dohlman CH. Treatment of superior limbic keratoconjunctivitis by thermocauterization of the superior bulbar conjunctiva. Ophthalmology 1986;93:162-6. Wander AH, Masukawa T. Unusual appearance of condensed chromatin in conjunctival cells in superior limbic keratoconjunctivitis. Lancet 1981;2:42-3. Wander AH, Neumeister RD, Tschismadia I, Choromokos EA, Masukawa T. In vivo corneal and conjunctival epithelial nuclear stain. Cornea 1985;4:8-13. Watanabe H, Maeda N, Kiritoshi A, Hamano T, Shimomura Y, Tano Y. Expression of a mucin-like glycoprotein produced by ocular surface epithelium in normal and keratinized cells. Am J Ophthalmol 1997;124:751-7. Watson S, Tullo AB, Carley F. Treatment of superior limbic keratoconjunctivitis with a unilateral bandage contact lens. Br J Ophthalmol 2002;86:485-6. Weissman SS, Char DH, Herbort CP, Ostler HB, Kaleta-Michaels S. Alteration of human conjunctival epithelial proliferation. Arch Ophthalmol 1992;110:357-9. Wilson FM, 2nd, Ostler HB. Superior limbic keratoconjunctivitis. Int Ophthalmol Clin 1986;26:99-112. Wright P. Superior limbic keratoconjunctivitis. Trans Ophthalmol Soc U K 1972;92:555-60. Yang HY, Fujishima H, Toda I, Shimazaki J, Tsubota K. Lacrimal punctal occlusion for the treatment of superior limbic keratoconjunctivitis. Am J Ophthalmol 1997;124:80-7. Yokoi N, Komuro A, Maruyama K, Tsuzuki M, Miyajima S, Kinoshita S. New surgical treatment for superior limbic keratoconjunctivitis and its association with conjunctivochalasis. Am J Ophthalmol 2003;135:303-8. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/34055 | - |
dc.description.abstract | 本研究計畫的宗旨是想要更深入去了解「上輪部角結膜炎(Superior limbic keraconjunctivitis, SLK)」,這個眼科門診中並不罕見的疾病,希望以稍大規模的臨床病例個案,來研究以「上部球結膜(superior bulbar conjunctiva)局部切除手術」治療那些對於藥物反應不良的病患,並利用其病理切片組織來研究肥胖細胞(Mast cell)及基質金屬蛋白酵素(Matrix metalloproteinases, MMPs)在上輪部角結膜炎中所扮演之角色。
自1992至2005年在臺大醫院眼科部門診當中,一共有三十位病人之四十個眼睛被包括在本研究當中,這些病人都是在確定診斷為上輪部角結膜炎後,使用局部藥物(包括局部類固醇眼藥水及人工淚液等眼藥)效果不佳之情形下,才接受上部球結膜局部切除手術,所有的病人在術前及術後皆有詳細的病歷紀錄其臨床症狀及徵兆。在醫療倫理委員會通過之情形下,這四十個眼睛之結膜病理切片皆進行後續的肥胖細胞、T與B淋巴球細胞及基質金屬蛋白酵素之免疫組織化學染色,而其中自2005年7月1日起接受前述結膜切除手術之病人,則一併收集其結膜組織進行反轉錄聚合酶連鎖反應,且在該同一時刻起,也收集因眼睛其他疾病於台大醫院接受眼科手術,但無上輪部角結膜炎患者,在病人知情同意且傷口關闔無虞之情形下,共取得二十位病人之結膜標本作為對照組。 所有四十個眼睛在手術後皆獲得臨床症狀及徵兆之緩解,唯獨其中有三個眼睛在結膜切除範圍之邊緣有病灶復發之情形,他們在接受第二次結膜切除手術後臨床症狀也都獲得完全的緩解。免疫組織化學染色方面則是顯示在上輪部角結膜炎組之肥胖細胞數目有顯著增加的趨勢(P = 0.004)。而反轉錄聚合酶連鎖反應則是顯示MMP-1與MMP-3在上輪部角結膜炎組與對照組有明顯的差異,MMP-2與MMP-9則是兩組沒有差別。再進一步以免疫組織化學染色來驗證MMP-1、MMP-2與MMP-3在病理切片中之情況,也證實MMP-1特別會聚集在肥胖細胞中(P < 0.0001),此外還有結膜表皮下之基質部分也會有基質金屬蛋白酵素的分布。 上輪部角結膜炎患者在臨床上對於局部眼藥反應不佳者,以上部球結膜局部切除手術來治療之效果非常明顯且無特別之併發症。而肥胖細胞數目增加以及MMP-1與MMP-3之表現增加的現象在此系列實驗中之上輪部角結膜炎患者也特別的明顯。因此,我們相信肥胖細胞以及基質金屬蛋白酵素包括MMP-1與MMP-3的增加,在上輪部角結膜炎之病理機轉應佔有一重要之角色。 | zh_TW |
dc.description.abstract | Although medication therapy for this not unusual disease, superior limbic keraconjunctivitis (SLK) had been done for years, failed results after this conservative treatment are commonly seen. Mostly, these patients with poor response to medication will be arranged conjunctival resection as therapy. Unfortunately, large scale of study for the effectiveness evaluation is absent. Therefore, we intend to explore the effectiveness of conjunctival resection in treating superior limbic keratoconjunctivitis (SLK) and the role of mast cell and matrix metalloproteinase (MMP) in SLK.
In this study, 40 eyes from 30 SLK patients since 1992 to 2005, who were unresponsive to medical treatment received superior bulbar conjunctival resection were selected. Another 20 patients from cataract and retinal surgery were served as control group. The conjunctiva specimens were examined by H-E stain and immunohistochemistry (IHC) using antibodies against mast cell tryptase, MMP-1, -2 and -3. All the fresh conjunctiva tissue including SLK group and control group were also processed to extract the total mRNA. Using MMP-1, -2, -3 and -9 as the primer, reverse transcription and polymerase chain reaction (RT-PCR) were also done in this study, In all operated eyes, the clinical symptoms and signs, including irritation/redness and superior bulbar conjunctival hyperemia / superior tarsal conjunctival papillary hypertrophy, subsided significantly one month after the operation. Only 3 eyes had recurrence from the margin of conjunctival resection, which were relieved after re-operation. Keratinized conjunctival epithelium, loss of goblet cells, increased mast cell numbers (P=0.004) and overexpression of MMP-1 and MMP-3 (P<0.0001) were found in SLK group. The results of RT-PCR were also compatible to that of IHC with the up-regulation of MMP-1 and MMP-3. Conclusively, our results demonstrate that superior bulbar conjunctival resection is an effective and safe treatment modality for SLK. The findings of immunohistochemistry and reverse transcription and polymerase chain reaction suggested that mast cells and up-regulation of MMPs play some roles in the pathogenesis of SLK. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T05:52:52Z (GMT). No. of bitstreams: 1 ntu-95-P93421002-1.pdf: 1435593 bytes, checksum: 3bf5effbf868a79ab66a3ed342ad514f (MD5) Previous issue date: 2006 | en |
dc.description.tableofcontents | 封面 ………………………………………………………………… 1
口試委員、指導教授與所長簽名表 ……………………………… 2 國家圖書館碩博士論文授權書 …………………………………… 3 致謝 ………………………………………………………………… 4 目錄 ………………………………………………………………… 5 圖表目錄 …………………………………………………………… 6 中文摘要 …………………………………………………………… 8 緒論 ………………………………………………………………… 9 實驗目的及研究假說 ………………………………………………14 研究方法與材料 ……………………………………………………15 結果 …………………………………………………………………18 討論 …………………………………………………………………22 展望 …………………………………………………………………27 論文英文簡述 ………………………………………………………28 參考文獻 ……………………………………………………………29 圖表 …………………………………………………………………34 | |
dc.language.iso | zh-TW | |
dc.title | 以上部球結膜局部切除手術治療上輪部角結膜炎研究及肥胖細胞與基質金屬蛋白酵素在上輪部角結膜炎中所扮演角色之探討 | zh_TW |
dc.title | Conjunctival Resection for the Treatment of Superior Limbic Keratoconjunctivitis (SLK) and the Involvement of
Mast Cells and Matrix Metalloproteinases in SLK | en |
dc.type | Thesis | |
dc.date.schoolyear | 94-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 賴明陽(Ming-Yang Lai),陳偉勵(Wei-Li Chen) | |
dc.subject.keyword | 上輪部角結膜炎,肥胖細胞,基質金屬蛋白酵素, | zh_TW |
dc.subject.keyword | Superior limbic keratoconjuncitivitis,Mast cell,Matrix metalloproteinase, | en |
dc.relation.page | 54 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2006-07-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-95-1.pdf 目前未授權公開取用 | 1.4 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。